Read our Recent Headlines

May 27 Biotech Update

Yesterday did not get any better and this is certainly not the start to the ASCO run up that the sector would want. That being said there was so little.

May 26 Biotech Update

What a bad start to the week and by bad I mean slow. The only sound we heard this morning was crickets. Nothing to move the sector in terms of.

13F Analysis of Best Performing Healthcare Hedge Funds (Q1 2015)

13F filings have arrived and it’s like Christmas day for me. I’ve been pouring through the filings, tweeting the interesting ones, and probably annoying everyone on twitter. These filings are.

May 22 Biotech Update

Yesterday sort of followed the potential new pattern of gaining strength throughout the day but volumes were a little low as we approach the holiday weekend. I suspect today will.

May 21 Biotech Update

It is a similar start to the trading day with the market sort of flat with the sector a little lower (with notable exceptions which will be discussed below). It.

May 20 Biotech Update

The market was off to a benign start but the sector seemed to take it on the chin (albeit on generally light volume). I am not sure why the selling.

May 19 Biotech Update

A mixed start to the morning with some red and green. It seems to me that the market generally wants to move higher but no one seems to have high.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!